Current Treatment Options in Gastroenterology

, Volume 5, Issue 6, pp 471–477 | Cite as

Variceal bleeding

  • Mark W. Russo

Opinion statement

Primary prophylaxis: Patients with cirrhosis who have esophageal varices but who have never had a bleeding episode may be treated medically or endoscopically. Without treatment, approximately 30% of cirrhotic patients with varices bleed and this risk is reduced by approximately 50% with therapy. Medical therapy includes nonselective beta blockers with or without nitrates. Compliance and side effects limit efficacy. Primary prophylaxis with endoscopic sclerotherapy is not warranted because of evidence suggesting that complications outweigh benefits. Studies of endoscopic therapy with ligation (endoscopic banding) demonstrate that in select patients (those with large varices), endoscopic banding may reduce the risk of first bleeding episode when compared with propranolol. Patients with large varices may benefit from a combination of banding with nonselective beta blockers. Secondary prophylaxis: After an initial variceal bleed, the risk of a second bleed is high and therapy is warranted to reduce the risk of rebleeding. The options are similar to those for primary prophylaxis, and in addition to medical and endoscopic therapy, transjugular intrahepatic portosystemic shunts (TIPS) and surgical shunts are therapeutic options. The combination of endoscopic therapy with medical therapy is the initial approach to prevent variceal rebleeding. Endoscopic banding is preferred to sclerotherapy because banding is associated with lower bleeding rates and fewer complications. TIPS is useful in cases refractory to endoscopic therapy or in uncontrolled variceal hemorrhage. Surgical shunts are typically reserved for patients in whom TIPS cannot be performed for technical reasons or for well-compensated cirrhotic patients. Acute variceal bleeding: Acute bleeding from esophageal varices requires an endoscopic evaluation and therapeutic intervention. Technically, endoscopic banding may not be possible because of limited visualization from bleeding and sclerotherapy is used because it is easier to perform in this setting. A continuous intravenous drip of octreotide should be initiated if variceal bleeding is suspected. If variceal bleeding cannot be controlled, then a Minnesota tube or Sengstaken-Blakemore tube should be placed by someone with experience. TIPS is effective rescue therapy for controlling acute variceal hemorrhage in circumstances when other methods fail.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sarin S, Lamda GS, Kumar M, et al.: Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999, 340:988–993. A large randomized study demonstrating that for patients with large varices (grade 3 or 4), endoscopic banding was associated with lower rebleeding rates compared with propranolol. However, the rebleeding rate in the propranolol group was higher than anticipated.PubMedCrossRefGoogle Scholar
  2. 2.
    Jutabha R, Jensen DM, Martin P, et al.: A randomized prospective study of prophylactic rubber band ligation compared with propranolol for prevention of first variceal hemorrhage in cirrhotics with esophageal varices. Gastrointest Endosc 2001, 53:568.Google Scholar
  3. 3.
    Garcio-Tsao G: Current management of complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120:726–748.CrossRefGoogle Scholar
  4. 4.
    Sarin S, Lahoti D, Saxena S, et al.: Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992, 16:1343–1349.PubMedCrossRefGoogle Scholar
  5. 5.
    Merkel C, Marin R, Sacerdoti D, et al.: Long-term results of a clinical trial of naldolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000, 31:324–329. A long-term study of 146 cirrhotic patients reporting efficacy and side effects of medical therapy.PubMedCrossRefGoogle Scholar
  6. 6.
    Merkel C, Marin R, Enzo E, et al.: Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996, 348:1677–1681.PubMedCrossRefGoogle Scholar
  7. 7.
    Poynard T, Cales P, Pasta L, et al.: Beta-adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter study group. N Engl J Med 1991, 324:1532–1538.PubMedCrossRefGoogle Scholar
  8. 8.
    Ideo G, Bellati G, Fesce E, Grimoldi D: Naldolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988, 8:6–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Teran JC, Imperiale TF, Mullen KD, et al.: Primary prophylaxis of variceal bleeding in cirrhotics: a cost effectiveness analysis. Gastroenterology 1997, 112:473–482.PubMedCrossRefGoogle Scholar
  10. 10.
    Garcia-Pagan JC, Villanueva C, Vila MC, et al.: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001, 121:908–914.PubMedCrossRefGoogle Scholar
  11. 11.
    Erstad BL: Octreotide for acute variceal bleeding. Ann Pharmacother 2001, 35:618–626.PubMedCrossRefGoogle Scholar
  12. 12.
    The Veterans Affairs Cooperative Variceal Sclerotherapy Group: Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med 1991, 324:1779–1784.CrossRefGoogle Scholar
  13. 13.
    Granlek IM, Jensen DM, Kovacs TOG, et al.: The economic impact of variceal hemorrhage. Cost-effectiveness implications of endoscopic therapy. Hepatology 1999, 29:44. Provides a thorough review of costs and efficacy of endoscopic therapy for esophageal variceal hemorrhage.CrossRefGoogle Scholar
  14. 14.
    Avgerinos A, Armonis A, Manolakopoulos S, et al.: Endoscopic sclerotherapy versus variceal ligation in the long term management of patients with cirrhosis after variceal bleeding: a prospective randomized study. J Hepatol 1997, 26:1034–1041.PubMedCrossRefGoogle Scholar
  15. 15.
    Saeed ZA, Steigmann GV, Ramirez FC, et al.: Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial. Hepatology 1997, 25:71–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Russo MW, Zacks SL, Sandler RS, Brown RS Jr: Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt versus endoscopic therapy for the prevention of esophageal variceal bleeding. Hepatology 2000, 31:358–363.PubMedCrossRefGoogle Scholar
  17. 17.
    Terblanche J: Portal hypertension management. Surgical Endoscopy 1993, 7:472–478.PubMedCrossRefGoogle Scholar
  18. 18.
    Russo MW, Jacques PF, Mauro M, et al.: Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl 2002, 8:271–277.PubMedCrossRefGoogle Scholar
  19. 19.
    Chalasani N, Clark WS, Martin LG, et al.: Determinant of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000, 118:138–44.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Mark W. Russo
    • 1
  1. 1.Division of Digestive Diseases CB#7080University of North Carolina HospitalsChapel HillUSA

Personalised recommendations